Safety and Efficacy of Herbmed Plus in Patients withRenal Calculi

RENAL CALCULI Clinical Trial

— HerbmedPlus  

Official title:

A Phase II, 28 Week, Randomized, Double- Blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 'Herbmed Plus' an Ayurvedic Formulation in Patients With Renal Calculi

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01355341
• Other study ID #: ACE/HMP-01
• Status: Unknown status
• Phase: Phase 2
• First received: May 16, 2011
• Last updated: May 17, 2011
• Start date: April 2010
• Est. completion date: December 2011

Study information

• Verified date: May 2011
• Source: Amai Charitable Trust
• Contact: PATANKAR B PATANKAR, MS.MCH
• Phone: 25434063
• Email: amaitrust[@]yahoo.co.in; suresh_iou[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

More specifically, the present invention relates to a 'Herbal Preparation' that is useful for

• Treatment of Renal calculi

• Reduction in the stone size & surface area

• The expulsion of stone

• Decreased need of Analgesic(Antiinflammatory Effect)

• Stops the recurrence and reformation of renal

Description:

1. Study duration 28 weeks

2. No. of Scheduled visits 8 visits

3. Study product Dose, Group one-:1capsule (of 500 mg) orally twice a day with meals for 24 weeks. Group two-:placebo1capsule (of 500 mg) orally twice a day with meals for 24 weeks.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 84
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 10 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 10-75 years (Both inclusive)

• Patients with Renal calculi, diagnosis confirmed by plain X-ray KUB &/or ultrasound KUB/CT scan Abdomen

• Size of the calculi ranging from 04 mm -09 mm

• Able and willing to give written informed consent and comply with the requirements of the study protocol

• Patients of reproductive potential (males and females) and willing to use a reliable means of contraception (e.g hormonal contraceptive patch, intrauterine device and physical barrier) throughout study participation

• Patients will to cooperate & give consent for the trial& comes for regular follow up.

Exclusion Criteria:

• Patients having acute condition of renal calculi.

• Any systemic disease requiring other medications of surgery for calculus condition.

• Complicated cases of Renal Calculi requiring surgical condition.

• Chronic or current infectious disease such as but not limited to chronic renal infection including active urinary tract infection.Uncontrolled diabetes, hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction

• Any other urogenital disorders.

• Liver dysfunction, defined as total bilirubin more then 1.5 the upper limit of Normal, aspartate aminotransferase more then 2.5 upper limit of Normal, or alanine aminotransferase more then 2.5 upper limit of Normal,

• Kidney disease, including serum creatinine level more then 1.5 upper limit of Normal,

• Subjects on herbal supplements for stone disease (plant extracts preparations or herbal medicines etc.) within previous 3 months.

• Participated in another clinical drug trial within 3 months before recruitment.

• Pregnancy or breast feeding

• Evidence of significant uncontrolled concomitant disease which in the Investigator's opinion would preclude patient participation

• Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline

• Patients with psychiatric illness or other condition that would limit compliance with study requirements

• Patients receiving or has received any investigational drug within 30 days before receiving the first dose of study medication

• Subjects who refuse to sign the informed consent document .

Related Conditions & MeSH terms

• Calculi
• Kidney Calculi
• Nephrolithiasis
• RENAL CALCULI

Intervention

Drug:
• HERBMED PLUS
500 mg Twice day for 6 month with lunch and dinner.

Locations

Country	Name	City	State
India	AMAI Charitable Trust's ACE Hospital Pune	Pune	Maharashatra

Sponsors (1)

Lead Sponsor	Collaborator
Amai Charitable Trust

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy of "Herbmed plus"in patients with urinary calculi by assessing the reduction in the stone size & surface area/ or the expulsion of stone		In 210 days
Secondary	Reduction in the size of stone Reduction in the density of the stone Painless expulsion of the stone/fragments Reduction in pain Consumption of Analgesics		In 210 days